Supported by

Stents, scaffolds and DCB

Find all the latest content on stents and scaffolds published on this website.

Since 1986, when the first cardiovascular stent was implanted, the development of drug-eluting stents (DES) and the recent introduction of bioresorbable scaffolds have revolutionised interventional cardiology. Keep up-to-date with the latest research; evolving tools, devices and techniques; the role of adjunctive pharmacotherapy; advances in imaging techniques as well as the use of invasive imaging and functional assessment. Find out more…

Filtered By
Stents, scaffolds and DCB

568 results

Strategic decision in stent failure

20 May 2025 – From EuroPCR 2025

Explore strategic decision-making in cases of stent failure in this session presenting complex clinical scenarios. Through detailed case analyses, including challenging left main trifurcation lesions and NSTEMI in the presence of chronic total occlusions, discover treatment approaches and key learnings to optimize patient outcomes.

Strategic decision in stent failure

DCB-PCI in de novo lesions

20 May 2025 – From EuroPCR 2025

Evaluate the role of drug-coated balloon (DCB) angioplasty in de novo coronary lesions with a focus on vessel diameter effects, comparisons to drug-eluting stents for small non-complex lesions, management of unstented dissections, high bleeding risk scenarios, and optimal dual antiplatelet therapy durations.

DCB-PCI in de novo lesions

PCR's Got Talent Round 1 - Session 1

20 May 2025 – From EuroPCR 2025

Experience a diverse range of cutting-edge interventional cardiology topics in PCR's Got Talent Round 1. This session features presentations on PFO closure outcomes, plaque morphology, vascular injury treatments, microvascular disease assessment, TAVI-related coronary obstruction prediction, novel FFR surrogates, and more.

PCR's Got Talent Round 1 - Session 1

Evolving bifurcation treatment practices: drug-coated balloons, angio-based FFR, and side branch optimisation

20 May 2025 – From EuroPCR 2025

Explore how bifurcation treatment is evolving with the integration of drug-coated balloons, angio-based FFR, and advanced side branch optimisation. This EuroPCR 2025 session highlights why DCB is gaining traction for bifurcation lesions and introduces the upcoming EBC-DCB trial comparing a stepwise DCB strategy to provisional DES...

Evolving bifurcation treatment practices: drug-coated balloons, angio-based FFR, and side branch optimisation

From theory to practice: the versatility of drug-coated balloons around the world

20 May 2025 – From EuroPCR 2025

Step into the world of drug-coated balloons (DCBs) with this EuroPCR 2025 session, tracing their journey from pioneering use in Europe to versatile applications worldwide. Discover the latest evidence on the safety and efficacy of both paclitaxel- and sirolimus-coated balloons across diverse lesion types—from straightforward to...

From theory to practice: the versatility of drug-coated balloons around the world

DCB in de novo lesions: new valid option?

20 May 2025 – From EuroPCR 2025

Explore the emerging role of drug-coated balloons (DCB) in treating de novo coronary lesions. This session discusses complexity management, comparisons with drug-eluting stents (DES), and the potential of DCBs as valuable alternatives, especially in high bleeding risk patients.

DCB in de novo lesions: new valid option?

Sirolimus coated balloon for coronary artery disease and peripheral artery disease treatment: the new frontier

20 May 2025 – From EuroPCR 2025

This EuroPCR 2025 session delivers a comprehensive update on the MagicTouch sirolimus-coated balloon (SCB) and its expanding role in treating both coronary and peripheral artery disease (CAD/PAD). The session covers the extensive clinical trial program supporting MagicTouch as a versatile treatment option across multiple indications. It...

Sirolimus coated balloon for coronary artery disease and peripheral artery disease treatment: the new frontier

Supraflex for high-risk patients and lesions: from practice to evidence-based medicine proven through FIRE and COMPARE

20 May 2025 – From EuroPCR 2025

Discover the latest evidence on the Supraflex thin-strut sirolimus DES in complex cases—from small vessels and diabetes to STEMI—supported by OCT analysis. This session highlights Supraflex’s performance in high bleeding risk and elderly patients, featuring data from FIRE, COMPARE, EARTH HBR, and Cruz Senior studies. Get...

Supraflex for high-risk patients and lesions: from practice to evidence-based medicine proven through FIRE and COMPARE

The future is now: QFR and RMS to optimise coronary artery disease patient management

20 May 2025 – From EuroPCR 2025

See how next-generation technologies are reshaping coronary artery disease treatment in this EuroPCR 2025 session. Learn how QFR is being used to plan PCI and evaluate results, and discover new insights into RMS technology—offering a potential leap beyond traditional drug-eluting stents. From practical case experience to...

The future is now: QFR and RMS to optimise coronary artery disease patient management

Intracoronary value for PCI optimisation

20 May 2025 – From EuroPCR 2025

Optimize your PCI strategies with intracoronary insights in this session highlighting plaque stabilization, coronary stent optimization under pressure, and the critical role of intravascular imaging beyond angiography. Learn management approaches for traumatic coronary artery dissection and explore diagnosis of delayed stent fracture using enhanced stent visualization...

Intracoronary value for PCI optimisation